Current stage-Stage II - intermediate risk Posts on Medivizor
Navigation Menu

Current stage-Stage II – intermediate risk Posts on Medivizor

Thalidomide for Multiple Myeloma.

Posted by on Nov 7, 2018 in Multiple Myeloma | 0 comments

In a nutshell This study aimed to compare the long-term effects of thalidomide (Immunoprin) to those of classic anti-cancer drugs in patients with recently diagnosed multiple myeloma. Thalidomide appeared effective but many patients experienced side-effects that affected treatment.  Some background Vincristine (Oncovin), doxorubicin...

Read More

Risk of adverse events in new versus conventional treatment for multiple myeloma

Risk of adverse events in new versus conventional treatment for multiple myeloma

Posted by on Apr 18, 2018 in Multiple Myeloma | 0 comments

In a nutshell This paper studied the risk of adverse events in patients who receive treatment for multiple myeloma. The use of new drugs increased the risk of low blood count, peripheral neuropathy and blood clots. Some background Multiple myeloma is a cancer of the plasma cells (type of white blood cell). Multiple myeloma can be treated with drugs...

Read More